Gain Therapeutics Inc (GANX) is destined for greater heights as its last quarter sales were 0 K

Zack King

On Monday, Gain Therapeutics Inc (NASDAQ: GANX) opened higher 6.39% from the last session, before settling in for the closing price of $2.66. Price fluctuations for GANX have ranged from $1.41 to $3.06 over the past 52 weeks.

A company in the Healthcare sector has dropped its sales by -37.02% annually for the last half of the decade. Company’s average yearly earnings per share was noted 27.42% at the time writing. With a float of $34.78 million, this company’s outstanding shares have now reached $35.98 million.

Gain Therapeutics Inc (GANX) Insider Updates

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Gain Therapeutics Inc is 3.65%, while institutional ownership is 12.03%.

Gain Therapeutics Inc (GANX) Performance Highlights and Predictions

If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.08 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.19) by 0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 27.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.30% during the next five years compared to -37.02% drop over the previous five years of trading.

Gain Therapeutics Inc (NASDAQ: GANX) Trading Performance Indicators

Check out the current performance indicators for Gain Therapeutics Inc (GANX). In the past quarter, the stock posted a quick ratio of 2.52.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.64, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.71 in one year’s time.

Technical Analysis of Gain Therapeutics Inc (GANX)

Let’s dig in a bit further. During the last 5-days, its volume was 0.94 million. That was better than the volume of 0.45 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 60.15%.

During the past 100 days, Gain Therapeutics Inc’s (GANX) raw stochastic average was set at 86.06%, which indicates a significant increase from 83.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.28 in the past 14 days, which was higher than the 0.17 volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $2.07, while its 200-day Moving Average is $1.92. However, in the short run, Gain Therapeutics Inc’s stock first resistance to watch stands at $2.91. Second resistance stands at $3.00. The third major resistance level sits at $3.12. If the price goes on to break the first support level at $2.70, it is likely to go to the next support level at $2.58. Assuming the price breaks the second support level, the third support level stands at $2.49.

Gain Therapeutics Inc (NASDAQ: GANX) Key Stats

There are currently 36,241K shares outstanding in the company with a market cap of 102.16 million. Presently, the company’s annual sales total 0 K according to its annual income of -20,410 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -5,280 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.